bioAffinity Technologies, Inc. priced its initial public offering at $0.80 a share, offering 1,040,000 shares of common stock, to list on the Nasdaq Capital Market under the symbol BIAF. It filed a Form S-1 registration statement for an initial public offering on September 11, 2024. As of November 6, 2026, its final prospectus is on file (Form 424B4, June 18, 2026).
Sell to companies like bioAffinity Technologies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
bioAffinity Technologies, Inc. filed a Form S-1 registration statement for an initial public offering on 2024-09-11. It has amended it 4 times. It filed its final prospectus on 2026-06-18, at a public offering price of $0.80 per share. Each fact below is quoted from the filing named with it.
Also on the record for bioAffinity Technologies, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 1, 2025 | Stake report, Schedule 13G, by Bigger Michael | 5.79% of the class | 5%+ stakes | Source |
Check before you invest in bioAffinity Technologies, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on bioAffinity Technologies, Inc. and the records around it.
bioAffinity Technologies, Inc. elsewhere on the record
- 5%+ stake filings Oct 2025
- Who owns it
Companies that share a holder
- BIGGER CAPITAL FUND L P also filed stake reports on 13 other companies: ClearPoint Neuro, Inc. (Nov 2026), Dermata Therapeutics, Inc. (Nov 2026), BTC Digital Ltd. (Oct 2026)
Also filing to list on the Nasdaq Capital Market
IPO filings on the Nasdaq Capital Market in Q2 2026, newest first.
- Tenon Medical, Inc. (Jun 2026)
- Exyn Technologies, Inc. (Jun 2026)
Watch bioAffinity Technologies, Inc.
Get an email when bioAffinity Technologies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on bioAffinity Technologies, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on bioAffinity Technologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on bioAffinity Technologies, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our common stock is listed on The Nasdaq Capital Market under the symbol “BIAF”.From the 424B4 filed 2026-06-18
Shares offered
We are offering 1,040,000 shares of our common stock, par value $0.007 per share at a public offering price of $0.80 per share.From the 424B4 filed 2026-06-18
Offering price
We are offering 1,040,000 shares of our common stock, par value $0.007 per share at a public offering price of $0.80 per share.From the 424B4 filed 2026-06-18
Use of proceeds
We intend to use the net proceeds from this offering for working capital and general corporate purposes.From the 424B4 filed 2026-06-18
Revenue
During the three months ended March 31, 2026, we generated revenue of approximately $1.4 million, and $6.2 million and $9.4 million during the years ended December 31, 2025, and December 31, 2024, respectively.From the S-1 filed 2026-06-12
Net loss or income
For the year 2024, cash used in operations was $7.1 million and net loss was $9.0 million.From the S-1/A filed 2025-05-05
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-09-11 | Registration statement filed | S-1 |
| 2024-11-27 | Registration statement filed | S-1 |
| 2025-04-11 | Registration statement filed | S-1 |
| 2025-05-02 | Registration statement filed | S-1 |
| 2025-05-05 | Registration statement amended | S-1/A |
| 2025-05-07 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-08-29 | Registration statement filed | S-1 |
| 2025-09-15 | Registration statement amended | S-1/A |
| 2025-09-24 | Registration statement filed | S-1 |
| 2025-09-25 | Registration statement amended | S-1/A |
| 2025-09-30 | Final prospectus filed: the offering is priced | 424B4 |
| 2026-04-30 | Registration statement filed | S-1 |
| 2026-06-12 | Registration statement filed | S-1 |
| 2026-06-16 | Registration statement amended | S-1/A |
| 2026-06-18 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for bioAffinity Technologies, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.